Swiss pharmaceutical company Novartis is laying off more than one in ten employees in Switzerland over the next three years – 1,400 of 11,600 jobs will go. It also plans to cut 8,000 of 108,000 jobs worldwide.
This content was published on
2 minutes
Keystone-SDA/ts
Español
es
Novartis eliminará 1 400 puestos de trabajo en Suiza
On Tuesday the Basel-based company informed its employees in detail about the wave of redundancies for the first time. All sites are affected.
Novartis confirmed corresponding reports by TA-Media newspapers in response to an enquiry from news agency AWP.
At the beginning of April Novartis announced a comprehensive restructuring, which it hopes will result in savings of at least $1 billion (CHF960 million) by 2024. The centrepiece is the merger of the previously separate divisions Innovative Pharmaceuticals and Cancer Drugs.
In addition to adapting its operational structure, Novartis is also simplifying its global functions in finance, human resources, legal and communications. This will eliminate positions across the company, according to a spokesperson.
“Novartis is making rapid progress in implementing these changes across the organisation and has already completed the appointment of most leadership teams at the global level,” he said.
The spokesperson added that the company was aware of the impact of these changes on employees and was ensuring that all consultation requirements were met, through representative bodies where appropriate.
In Switzerland, formal consultations with employee representatives at the non-management level and consultations with management in the affected areas were already underway, he said.
More
More
Novartis: The making of a pharma giant
This content was published on
The company formed when Ciba Geigy and Sandoz merged and analysts say it’s a big success. The merger cost around 10,000 jobs but in the long-run more were created. The current CEO concedes that the merger also meant the loss of the Ciba corporate identity. Novartis’ profits shrank by a third in 2015, partly because…
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
Swiss climate activists block vehicles near Gotthard tunnel
This content was published on
Around ten climate activists briefly blocked the A2 motorway near the northern entrance of the Gotthard tunnel on Thursday.
Watches belonging to Michael Schumacher up for auction
This content was published on
Schumacher's family is auctioning off eight rare watches from his collection in Geneva. The Christie's auction will take place on Monday.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis to cut 2,200 Swiss jobs by 2020
This content was published on
Around 1,500 jobs are affected in production and 700 in services. Novartis currently employs 13,000 people across Switzerland.
This content was published on
Swiss pharmaceutical firm Novartis filed the most international trademark applications with the World Intellectual Property Organization (WIPO) .
Novartis pays big fine for bribing doctors in the US
This content was published on
Swiss pharma company Novartis will pay $729 million to US authorities in an out-of-court settlement over charges that the company bribed doctors to use its drugs.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.